title: Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologists.
abstract: OBJECTIVE
  Despite the development of consensus guidelines in ulcerative colitis (UC), there remain several areas of uncertainty in the everyday management of this incompletely understood disease. We performed a national vignette survey to measure variations in decision-making in areas of controversy.
  
  
  METHODS
  We constructed a survey with 3 vignettes to measure decision-making in 4 areas of controversy in UC: (1) dysplasia management, (2) mesalamine dosing, (3) diagnostic testing for underlying Crohn's disease, and (4) treatment of steroid-refractory inpatient UC. We compared responses between a group of community gastroenterologists and UC experts.
  
  
  RESULTS
  We received 192 responses (36% response). Compared with community gastroenterologists, UC experts were more likely to endorse colectomy for both unifocal and multifocal low-grade dysplasia, use narrow band imaging and chromoendoscopy for surveillance colonoscopy, use high-dose mesalamine for inducing remission, use long-term mesalamine for cancer chemoprevention, order computed tomography enterography to evaluate for Crohn's disease, and to have a lower threshold to call for surgery consultation in steroid-refractory UC. There was little agreement regarding the optimal frequency of surveillance colonoscopy, even among experts. Most respondents favored using infliximab over cyclosporine in steroid-refractory UC.
  
  
  CONCLUSIONS
  Community gastroenterologists and UC experts vary dramatically in their approach to many areas of uncertainty in UC. The only area of consensus between groups is the use of infliximab over cyclosporine in steroid-refractory UC, itself a controversial decision. These data suggest that current practice patterns are highly disparate and focus attention on specific areas of disconnect that should be further investigated.
authors.affiliation: Veteran's Administration Greater Los Angeles Healthcare System, Los Angeles, California, USA. bspiegel@mednet.ulca.edu
authors.forename: Brennan M R
authors.initials: BM
authors.lastname: Spiegel
authors.forename: Wayne
authors.initials: W
authors.lastname: Ho
authors.forename: Eric
authors.initials: E
authors.lastname: Esrailian
authors.forename: Stephan
authors.initials: S
authors.lastname: Targan
authors.forename: Peter D R
authors.initials: PD
authors.lastname: Higgins
authors.forename: Corey A
authors.initials: CA
authors.lastname: Siegel
authors.forename: Marla
authors.initials: M
authors.lastname: Dubinsky
authors.forename: Gil Y
authors.initials: GY
authors.lastname: Melmed
mesh_terms: D000328:Adult; D003093:Colitis, Ulcerative / Q000175:diagnosis* / Q000628:therapy*; D003424:Crohn Disease / Q000175:diagnosis; D003625:Data Collection; D003657:Decision Making; D003955:Diagnostic Tests, Routine / Q000706:statistics & numerical data; D005260:Female; D006302:Health Services Research / Q000706:statistics & numerical data*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D011795:Surveys and Questionnaires
chemical_list: D007166:Immunosuppressive Agents